We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03344367
Recruitment Status : Unknown
Verified July 2019 by Jun Zhu, Peking University Cancer Hospital & Institute.
Recruitment status was:  Active, not recruiting
First Posted : November 17, 2017
Last Update Posted : July 12, 2019
Shanghai Mingju Biotechnology Co., Ltd.
Information provided by (Responsible Party):
Jun Zhu, Peking University Cancer Hospital & Institute

Brief Summary:
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of infusion of autologous CD19-targeted chimeric antigen receptor (CD19 CAR) T cells in adult subjects with relapsed and refractory B-cell Non-Hodgkin lymphoma.

Condition or disease Intervention/treatment Phase
Non Hodgkin Lymphoma Biological: JWCAR029 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Adult Subjects With Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Actual Study Start Date : November 16, 2017
Estimated Primary Completion Date : October 2019
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: JWCAR029
The safety and efficacy of JWCAR029 will be evaluated in a standard 3+3 dose escalation approach. 5 CAR T dosage will be tested in this study: 1×10^7, 2.5×10^7, 5×10^7, 1×10^8, 1.5^108 CAR+ T cells.
Biological: JWCAR029
Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JWCAR029. During JWCAR029 production, subjects will receive a conditioning chemotherapy regimen of cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with JWCAR029 by intravenous (IV) injection.

Primary Outcome Measures :
  1. Treatment-related adverse events (AEs) [ Time Frame: 2 years ]
    Physiological parameter

  2. Dose-limiting toxicities of JWCAR029 [ Time Frame: 28 days after JWCAR029 infusion ]
    Physiological parameter

  3. Objective response rate (ORR) [ Time Frame: 2 years ]
    Lugano criteria

Secondary Outcome Measures :
  1. Maximum concentration (Cmax) of JWCAR029 in the peripheral blood and bone marrow [ Time Frame: 1 year after JWCAR029 infusion ]
    Flow cytometry and qPCR

  2. Time to maximum concentration (Tmax) of JWCAR029 in the peripheral blood and bone marrow [ Time Frame: 1 year after JWCAR029 infusion ]
    Flow cytometry and qPCR

  3. Area-under the concentration-vs-time-curve (AUC) of JWCAR029 in the peripheral blood and bone marrow [ Time Frame: 1 year after JWCAR029 infusion ]
    Flow cytometry and qPCR

  4. Complete response (CR) rate [ Time Frame: 2 years ]
    Lugano criteria

  5. Duration of response [ Time Frame: 2 years ]
    Lugano criteria

  6. Progression-free survival (PFS) and PFS ratio [ Time Frame: 2 years ]
    Lugano criteria

  7. Overall survival [ Time Frame: 2 years ]
    Physiological parameter

  8. Health-related quality of life (HRQoL) [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must meet all of the following criteria to be enrolled in this study:

    1. Age ≥ 18 years at the time of consent
    2. Signed written informed consent obtained prior to any study procedures
    3. Relapsed or refractory B-cell NHL.
    4. PET-positive disease BY Lugano classification
    5. Archived tumor biopsy tissue available from the last relapse and corresponding pathology report available or, if at least one tumor-involved site is deemed accessible at time of screening, willing to undergo pre-treatment biopsy (excisional when possible) for disease confirmation. If a subject has never had a complete response, a sample from the most recent biopsy is acceptable.
    6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    7. Adequate bone marrow, renal, hepatic, pulmonary and cardiac function
    8. Adequate vascular access for leukapheresis procedure
    9. Subjects who have received previous CD19-targeted therapy must have CD19-positive lymphoma confirmed on a biopsy since completing the prior CD19-targeted therapy
    10. Subjects must agree to use appropriate contraception.

Exclusion Criteria:

  • Subjects who meet any of the following criteria will be excluded from participation in this study:

    1. Subjects with central nervous system (CNS)-only involvement by malignancy (note: subjects with secondary CNS involvement are allowed on study)
    2. History of another primary malignancy that has not been in remission for at least 2 years.
    3. Treatment with alemtuzumab within 6 months of leukapheresis, or treatment with fludarabine or cladribine within 3 months of leukapheresis
    4. Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection at the time of screening
    5. Subjects with uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate antibiotics or other treatment at the time of leukapheresis or JWCAR029 administration
    6. Presence of acute or chronic graft-versus-host disease (GVHD)
    7. History of cardiovascular disease
    8. History or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
    9. Pregnant or nursing women.
    10. Prior CAR T-cell or other genetically-modified T-cell therapy, with the exception of prior JWCAR029 treatment in this protocol for subjects receiving retreatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03344367

Layout table for location information
Beijing Cancer Hospital
Beijing, China, 100142
Sponsors and Collaborators
Peking University
Shanghai Mingju Biotechnology Co., Ltd.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Jun Zhu, Professor, Peking University Cancer Hospital & Institute
ClinicalTrials.gov Identifier: NCT03344367    
Other Study ID Numbers: JWCAR029-001
First Posted: November 17, 2017    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Jun Zhu, Peking University Cancer Hospital & Institute:
Non Hodgkin Lymphoma
CD19-targeted chimeric antigen receptor
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases